Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.
A new blood test analyzing cell-free DNA methylation patterns may help identify the type and source of liver transplant injuries weeks before clinical diagnosis.